Compare · NTRA vs RDNT
NTRA vs RDNT
Side-by-side comparison of Natera Inc. (NTRA) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $31.91B, about 7.2x RDNT ($4.42B).
- Over the past year, NTRA is up 35.0% and RDNT is down 5.3% - NTRA leads by 40.2 points.
- NTRA has been more active in the news (18 items in the past 4 weeks vs 9 for RDNT).
- NTRA has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Natera Inc.
- RadNet Inc.
- Price
- $222.87+4.43%
- $56.18+3.65%
- Market cap
- $31.91B
- $4.42B
- 1M return
- +15.05%
- -3.49%
- 1Y return
- +34.95%
- -5.26%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 18
- 9
- Recent ratings
- 25
- 10
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest NTRA
- Director Marcus Gail Boxer sold $2,389,328 worth of shares (11,000 units at $217.21) and exercised 11,000 shares at a strike of $22.83 (SEC Form 4)
- SEC Form 3 filed by new insider Lynch Thomas J. Jr.
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
Latest RDNT
- RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Swartz David L was granted 2,946 shares, increasing direct ownership by 2% to 179,712 units (SEC Form 4)
- Director Spurlock Gregory E. was granted 2,946 shares, increasing direct ownership by 56% to 8,236 units (SEC Form 4)
- Director Jacobs Laura Pastre was granted 2,946 shares, increasing direct ownership by 11% to 29,953 units (SEC Form 4)
- Director Levitt Lawrence L was granted 2,946 shares, increasing direct ownership by 2% to 167,902 units (SEC Form 4)
- RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
- RadNet to Host Men's Health Webinar on June 13, 2026
- Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
- SEC Form SCHEDULE 13G filed by RadNet Inc.